US FDA Concludes Pre-Approval Inspection of Aurobindo Pharma Subsidiary; 5 Observations Noted
Aurobindo Pharma Limited has received the conclusion report following a Pre-Approval Inspection (PAI) conducted by the United States Food and Drug Administration (US FDA) at its subsidiary facility. The inspection, which took place in Andhra Pradesh, recorded five observations that the company is committed to responding to within the stipulated time frame.The US FDA conducted the PAI at Eugia Steriles Private Limited, a 100% subsidiary of Eugia Pharma Specialities Limited and a stepdown subsidiary of Aurobindo Pharma. The facility is located in Parawada Mandal, Anakapalli District, Andhra Pradesh. The inspection spanned from June 10, 2026, to June 19, 2026.
The company affirmed its commitment to maintaining the highest quality manufacturing standards across all its global facilities.
A summary of the inspection outcome and impact is detailed below:
| Authority | Inspection Period | Observations | Financial/Operational Impact |
|---|---|---|---|
| US Food and Drug Administration (US FDA), USA | June 10, 2026 - June 19, 2026 | 5 observations | No impact on the Company's financials or operations. |
Aurobindo Pharma confirmed that there is no current financial or operational impact on the company as a result of the PAI findings. The management team intends to respond promptly to the five observations raised by the US FDA.
AUROPHARMA Stock Price Movement
On Friday, Aurobindo Pharma Limited shares edged higher, gaining 3.87% and settling at ₹1497.80. The stock traded briskly in the market, with over 2.5 million shares changing hands during the session.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.